| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T166 |
0-45 |
Sentence |
denotes |
Scaffolding of cell‐bound mAbs by FcγR+ cells |
| T167 |
46-147 |
Sentence |
denotes |
FcγR‐expressing cells can be critical, but passive, participants in the MOA of some mAbs (Figure 1e). |
| T168 |
148-360 |
Sentence |
denotes |
In FcγR scaffolding, IgG mAb molecules that have opsonized the cell surface of a target cell are additionally cross‐linked by their Fc portions engaging the FcγRs that are arrayed on the surface of a second cell. |
| T169 |
361-573 |
Sentence |
denotes |
This “super‐cross‐linking” of the target‐bound mAb by the FcγR lattice or “scaffold” on the adjacent cell greatly exceeds the target cross‐linking by the mAb alone, thereby inducing a response in the target cell. |
| T170 |
574-1167 |
Sentence |
denotes |
Scaffolding was originally identified as the basis of T‐cell mitogenesis induced by anti‐CD3 mAb.57, 58 The CD3 mAbs alone were poor mitogens but the “super‐cross‐linking” of the T‐cell‐bound CD3 mAb by the membrane FcγR on adjacent cells, particularly by monocytes, induced rapid T‐cell expansion and cytokine secretion but did not require activation of FcγR‐expressing cells.57 Regrettably, FcγR scaffolding came to prominence and clinical relevance because of its causal role in the catastrophic adverse events resulting from the administration of anti‐CD357 and anti‐CD28 (TGN1412)59 mAbs. |
| T171 |
1168-1303 |
Sentence |
denotes |
Nonetheless, FcγR scaffold‐based induction of intracellular responses in a target cell can also lead to beneficial therapeutic effects. |
| T172 |
1304-1526 |
Sentence |
denotes |
Such examples are the induction of apoptotic death in a target cell, which is likely part of the MOA of daratumumab in multiple myeloma60 or the controlled agonistic expansion of cells, for example, via CD40 mAb agonism.43 |
